8-K: Molecular Templates Provides Promising Interim Clinical Updates for Cancer and Immune Disease Therapies

Molecular Templates reports positive interim clinical data for its MT-6402 and MT-0169 therapies, showing potential in treating solid tumors and immune-mediated diseases.

Summary

• Molecular Templates has released an update on its clinical-stage programs, highlighting the potential of its Engineered Toxin Body (ETB) platform.
• MT-6402, targeting PD-L1, has shown monotherapy activity in patients with relapsed or refractory solid tumors, including partial responses in head and neck and lung cancer patients.
• Two head and neck cancer patients with low PD-L1 expression achieved partial responses and remain in good condition after 21 and 12 cycles of treatment, respectively.
• A non-small cell lung cancer patient with high PD-L1 expression achieved a partial response after 8 cycles, having previously progressed on other therapies.
• MT-0169, targeting CD38, has demonstrated potent depletion of CD38+ immune cells in early clinical data, with no significant adverse events.
• MT-0169 shows potent activity against plasma cells with IC50 activity in the picomolar or femtomolar range.
• MT-8421, targeting CTLA-4, has shown early pharmacodynamic effects, including peripheral depletion of Tregs and elevations in IL-2, with two patients showing stable disease.
• All three therapies have shown a favorable safety profile with no drug-related adverse events exceeding grade 3.

Sentiment

Score: 8

Explanation: The document presents positive clinical data with promising results, a favorable safety profile, and a clear path forward for the company's pipeline. The risks are acknowledged but do not overshadow the positive developments.

Positives

• MT-6402 has shown promising monotherapy activity in heavily pre-treated cancer patients, including partial responses in head and neck and lung cancer.
• MT-0169 has demonstrated potent depletion of CD38+ immune cells, suggesting potential in treating immune-mediated diseases.
• All three therapies, MT-6402, MT-0169, and MT-8421, have shown a favorable safety profile with no drug-related adverse events exceeding grade 3.
• MT-0169 shows potent activity against plasma cells with IC50 activity in the picomolar or femtomolar range.
• MT-8421 has shown early pharmacodynamic effects, including peripheral depletion of Tregs and elevations in IL-2.

Negatives

• One lung cancer patient in the MT-6402 study passed away from COVID and was not evaluable.
• One patient in the MT-8421 study had disease progression at the end of cycle 2.

Risks

• The company's ability to secure continued financing on commercially reasonable terms is a risk.
• The company's cash resources may not be sufficient to fund its continuing operations.
• The results of ongoing clinical studies may not be representative of future results.
• The company's ability to maintain its Nasdaq listing is a risk.
• The company's ability to effectively operate and retain key employees after a reduction in force is a risk.

Future Outlook

Molecular Templates plans to continue developing MT-0169 in hematology and is evaluating its potential in severe immune-mediated diseases. They will also continue enrollment in ongoing clinical trials for MT-6402 and MT-8421.

Management Comments

• Eric Poma, PhD., Chief Executive and Chief Scientific Officer of MTEM, stated, 'ETBs are a potentially powerful therapeutic approach to selectively depleting immunosuppressive cells in oncology or eliminating self-reacting immune cells in severe immune-mediated diseases.'
• He also noted that the monotherapy activity seen with MT-6402 and the clinical and ex vivo depletion of CD38+ immune cells seen with MT-0169 underscore the potential of this platform across multiple diseases.

Industry Context

The announcement highlights the growing interest in targeted biologic therapies for cancer and immune-mediated diseases. The use of ETBs represents a novel approach compared to traditional antibodies and small molecule drugs. The focus on depleting specific cell types, such as immunosuppressive cells in cancer and self-reacting immune cells in autoimmune diseases, aligns with current trends in immunotherapy.

Comparison to Industry Standards

• The partial response rates observed with MT-6402 in heavily pre-treated head and neck cancer patients are encouraging, especially given the low PD-L1 expression in these patients. This compares favorably to some checkpoint inhibitor therapies which often show limited efficacy in low PD-L1 expressing tumors.
• The observed depletion of CD38+ immune cells with MT-0169 is consistent with the mechanism of action of CD38-targeting antibodies like daratumumab, but the unique mechanism of action of MT-0169 may overcome resistance mechanisms seen with these antibodies.
• The early pharmacodynamic effects of MT-8421, including Treg depletion and IL-2 elevation, are similar to what is seen with other CTLA-4 inhibitors, but the ETB approach may offer a more potent and targeted effect.

Stakeholder Impact

• Shareholders may react positively to the promising clinical data and the potential of the company's ETB platform.
• Employees may be encouraged by the progress of the company's clinical programs.
• Patients with cancer and immune-mediated diseases may benefit from the development of these novel therapies.
• The company's suppliers and partners may see increased opportunities for collaboration.

Next Steps

• Molecular Templates will continue to enroll patients in ongoing clinical trials for MT-6402 and MT-8421.
• The company will continue to develop MT-0169 in hematology and evaluate its potential in severe immune-mediated diseases.

Key Dates

Keywords

ETB, Engineered Toxin Bodies, MT-6402, MT-0169, MT-8421, PD-L1, CD38, CTLA-4, Cancer, Immune-mediated diseases, Monotherapy, Clinical trial, Biologics, Immunosuppressive cells, Tregs